MemorEM
Phase 2- Indications
- Alzheimer's disease
Company intelligence / Profile preview
NeuroEM Therapeutics
Tampa, Florida, United Statesneuroem.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Early preclinical and human feasibility studies have shown that the TEMT-RF device can safely improve cognitive function in Alzheimer’s patients, with evidence of breaking up toxic beta amyloid and tau proteins. The company has completed a landmark human study demonstrating significant cognitive improvement, and pivotal trials are ongoing to support regulatory approval.
- Therapeutic areas
- Neurology
- Modalities
- Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF)
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
1 asset03
Partnerships
University of South Florida / USF Health Byrd Alzheimer’s InstituteLeft Coast EngineeringRF Exposure LabOcotillo ElectromagneticsRemarkable TechnologiesAxiom Clinical Research of FloridaInvicro/Konica MinoltaMegaNano Biotech Inc.
Beyond the preview
Go deeper on NeuroEM Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuroEM Therapeutics.